Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

Chinese Biotech Firm VISEN Raises $150m Led by Sequoia Capital China

By DealStreetAsia / Jan 12, 2021 01:53 PM / Finance

Photo: Visual China

Photo: Visual China

Shanghai-based endocrine therapy developer VISEN Pharmaceuticals has raised an aggregate of $150 million in its Series B round to facilitate its development in the Greater China region.

Sequoia Capital China has led the said round with the participation of a slew of new investors including OrbiMed, HBM Healthcare Investments, Logos Capital and Cormorant Asset Management, Sherpa Healthcare Partners, Pivotal bioVenture Partners China, and CDG Capital.

Existing backers Ascendis Pharma, Sofinnova Investments and Vivo Capital also re-upped in the round. The three investors jointly set up VISEN in 2018.

Since its inception, the firm claims to be developing the unmet medical needs for patients who suffer from endocrine diseases in the Greater China region like mainland China, Hong Kong, Macau and Taiwan.

“Series B funding will help to accelerate our clinical development, manufacturing, and commercialization of our three leading products, and establish a strong foundation on which we will enrich our pipeline from diversified international partnerships,” said VISEN Pharmaceuticals CEO and board member Pony Lu in a statement.

Late last year, Sequoia Capital China made headlines when it partnered with LYFE Capital, Xiamen C&D Emerging Industry Equity Investment, and others, collectively investing 600 million yuan ($92 million) in US customized biology research reagents and services provider ABclonal Technology.

Contact editor Marcus Ryder (marcusryder@caixin.com)

Related: Liu He Calls for China to Get Technologically Self-Reliant, Fast


Share this article
Open WeChat and scan the QR code